Metropolitan Life Insurance CO Atreca, Inc. Transaction History

Metropolitan Life Insurance CO

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$7.82 - $13.8 $62 - $110	-8 Closed	0 $0
Q1 2021 Jun 26, 2023	BUY	$13.0 - $19.34 $103,831 - $154,468	7,987 New	7,987 $122 Million
Q1 2021 Mar 30, 2023	SELL	$13.0 - $19.34 $12,831 - $19,088	-987 Reduced 11.0%	7,987 $122,000
Q1 2021 May 14, 2021	SELL	$13.0 - $19.34 $116,558 - $173,402	-8,966 Reduced 99.91%	8 $122,000
Q4 2020 Jun 22, 2023	BUY	$13.03 - $17.09 $116,931 - $153,365	8,974 New	8,974 $144,000
Q3 2020 Jun 26, 2023	BUY	$12.67 - $23.19 $113,700 - $208,107	8,974 New	8,974 $125,000
Q3 2020 Mar 30, 2023	BUY	$12.67 - $23.19 $38,314 - $70,126	3,024 Added 50.82%	8,974 $125,000
Q3 2020 Nov 13, 2020	BUY	$12.67 - $23.19 $38,314 - $70,126	3,024 Added 50.82%	8,974 $125,000
Q2 2020 Jun 26, 2023	BUY	$12.52 - $23.45 $74,494 - $139,527	5,950 New	5,950 $126,000
Q1 2020 Jul 12, 2023	BUY	$11.4 - $27.28 $67,830 - $162,316	5,950 New	5,950 $98,000
Q1 2020 Mar 30, 2023	BUY	$11.4 - $27.28 $67,830 - $162,316	5,950 New	5,950 $98,000
Q1 2020 May 15, 2020	BUY	$11.4 - $27.28 $67,830 - $162,316	5,950 New	5,950 $98,000

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.